Confidential mandate
Finance Director — Medical-Equipment Operating Cover
Urgent / Replacement
Finance Director mandate in Chennai, India · Medical Equipment
A nine-month finance leadership assignment will provide operating accountability across medical-equipment cash, margin and reporting decisions, and transfer a controlled cycle to the permanent appointee.
The mandate
Medical-equipment sales, installation and service teams require integrated finance leadership to align interpretations of when margin and cash become reliable. Equipment may be delivered before commissioning is complete, service coverage can begin before invoicing assumptions are settled, and imported inventory carries currency exposure well before collection. The bridge must hold these decisions together rather than treating finance as a retrospective reporting desk.
The intended start is 19 October 2026 for nine months, with a permanent search commencing immediately. Chennai is the primary base; visits to Indian service and distribution operations are planned around evidence needs. Regional discussions can be remote. Any extension requires a new written decision and revised end conditions, not an assumption that temporary availability should compensate indefinitely for recruitment delay.
Handover will require an accepted equipment-to-service profitability bridge, a validated inventory and currency exposure register, and three closes with unresolved judgements separately approved. The incoming director must complete a supervised cash forecast and review the highest-risk customer balances. Success means the retained team can explain the difference between booked equipment margin, lifetime service economics and cash at risk without relying on the bridge holder's personal judgement notes.
The director may approve operating finance schedules, forecast assumptions and cash deployment within sanctioned facilities. Customer credit exceptions above ₹25 lakh, borrowing changes, inventory write-offs above ₹20 lakh and permanent management recruitment go through existing approvers. Statutory sign-off stays with appointed officers. Treasury execution follows approved instruments and exposure limits; an interim title is not permission to speculate on exchange rates.
Product safety, clinical performance claims and technical service quality are outside the finance seat. The appointment also excludes legal dispute representation and redesign of the full regional tax structure. It does include challenging commercial terms whose financial effects are not supported, making the cost of warranty and service commitments visible, and protecting close control while operational priorities compete.
What you will own
- Approve equipment and service margin reviews that identify commissioning, warranty and collection dependencies before recognising forecast improvement or committing cash against expected equipment collections.
- Set a weekly cash decision sheet connecting customer receipts, import payments and approved foreign-exchange coverage, flagging timing gaps for authorised funding or maturity decisions.
- Authorize inventory ageing actions only after service demand, technical usability and disposal evidence have been checked against operational requirements and approved accounting treatment.
- Resolve forecast disputes using documented shipment, installation and contractual evidence rather than sales-pipeline confidence alone, making competing interpretations visible to the managing director.
- Institute close sign-off for material revenue, provision and currency judgements, with retained specialists owning supporting schedules and independent reviewers approving the adjustment basis.
- Induct the successor through customer-credit reviews, treasury limits and an independently replayed equipment-to-service performance cycle, requiring explanation of unresolved commercial and accounting exposures.
Candidate qualifications
- Show eighteen or more years in finance with director or equivalent country-controller accountability in medical equipment, healthcare technology or related manufacturing. Explain an installation or service-contract decision where you changed the financial outcome, identifying your authority, the commercial constraint and the realised cash or margin result rather than only the size of the business.
- Demonstrate strong controllership across inventory, revenue, warranty and foreign-currency balances under Ind AS with regional reporting interfaces. Provide a reviewed judgement where equipment and service obligations required different treatment, and show how you ensured sales reporting did not outrun the evidence supporting statutory recognition.
- Bring treasury capability grounded in exposure identification and approved hedging execution. A relevant professional finance qualification is expected; foreign-exchange training is useful but must be supported by an actual decision record. Explain a case where apparently attractive hedge coverage created a maturity or cash mismatch and how you corrected it within policy.
- Prove leadership of planning and accounting managers through a demanding operating cycle. Describe how you assigned judgement ownership, preserved independent review and transferred a forecast to another leader. Candidates must distinguish delegated finance authority from medical, legal and statutory authority, and demonstrate readiness for the specified start and regular Chennai presence.
Application
Applications for this mandate are received in one way only: through the India Board Terminal's application process. It is automated end to end. Your Executive Passport travels to the mandate holder in its confidential form, your answers to the three questions below are read before anything else in your file, and every stage that follows is recorded on your applications page.
There is no address to write to and no intermediary to call. The mandate holder reads what the Terminal delivers and nothing else, which is what keeps the process the same for every applicant and keeps your name out of it until you release it. Applications close on 10 October 2026. Mandate reference PCT-INT-2026-IND-42.
More seats like this one
This mandate is confidential. The client is named only under a mutual NDA, and your own record is never listed, sold or shown to a company under your name until you release it for this specific mandate.